Obiettivo Human primary immunodeficiencies affecting cytotoxic lymphocyte function are associated with high morbidity and mortality. They often present as hyperinflammatory syndromes triggered by viral infections, hematological malignancies, or systemic autoimmunity. Although recent advances have provided molecular diagnoses for some of the most severe cases, only a handful of genes have been identified and disease in a majority of patients cannot be explained by current insights. My work has elucidated fundamental mechanisms of lymphocyte cytotoxicity. Furthermore, my group is leading international efforts in developing sensitive assays of human lymphocyte cytotoxicity. Some of our assays have been implemented for clinical diagnostics world-wide. Recently, we have also identified new, widespread mutations that explain many cases of fatal immunodeficiencies early in life. We now seek support for taking such studies to yet a higher level. The outlined interdisciplinary approach presented here aims at evaluating cytotoxic lymphocyte development and function in large numbers of patients, in addition to healthy individuals in a complementary approach, using state-of-the-art methodology. We will employ next-generation sequencing to identify novel genes associated with disease. The significance of putative mutations for lymphocyte cytotoxicity will be assessed using cutting-edge experimental platforms. Together, such genotype-immunotype studies promise to reveal novel genes associated with disease and further provide understanding of human genetic diversity. Thus, these studies can directly benefit patients through improved diagnosis, aiding targeted treatments, and offer new insights into human cytotoxic lymphocyte development and function with relevance to health. Insights will also pave the way for prospective, population-based molecular epidemiology studies required to more accurately assess the panorama of diseases associated with congenital defects in lymphocyte cytotoxicity. Campo scientifico social sciencessociologydemographymortalitymedical and health scienceshealth sciencespublic healthepidemiologynatural sciencesbiological sciencesgeneticsmutation Programma(i) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Argomento(i) ERC-SG-LS6 - ERC Starting Grant - Immunity and infection Invito a presentare proposte ERC-2012-StG_20111109 Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-SG - ERC Starting Grant Istituzione ospitante KAROLINSKA INSTITUTET Contributo UE € 1 499 996,00 Indirizzo Nobels Vag 5 17177 Stockholm Svezia Mostra sulla mappa Regione Östra Sverige Stockholm Stockholms län Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Klas Karlsson (Mr.) Ricercatore principale Yenan Bryceson (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato Beneficiari (1) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto KAROLINSKA INSTITUTET Svezia Contributo UE € 1 499 996,00 Indirizzo Nobels Vag 5 17177 Stockholm Mostra sulla mappa Regione Östra Sverige Stockholm Stockholms län Tipo di attività Higher or Secondary Education Establishments Contatto amministrativo Klas Karlsson (Mr.) Ricercatore principale Yenan Bryceson (Dr.) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Costo totale Nessun dato